Risk of prolonged or discontinued new drug development
First written in FY2017. 5 of 6 entries say "Restated". Latest entry: FY2026.
The whole theme swung hardest in 2022: 22 of 44 companies on the "Worse" side.
30 other companies' latest entry also says "Restated".
- FY2026RestatedAnnual report
「Pharmaceutical research and development requires substantial funding and a long development period of more than 10 years, but the probability that these efforts will result in a new product or technology is by no means high.」
The company continues to report the risk that research and development requires a long period and substantial funding and may be discontinued. - FY2022RestatedAnnual report
「Pharmaceutical research and development requires substantial funding and a long development period of more than 10 years, but the probability that these efforts will result in a new product or technology is by no means high.」
The company continues to report the risk that development may be discontinued if the expected efficacy or safety cannot be confirmed, after substantial funding and a long period are required for research and development. - FY2021RestatedAnnual report
「Pharmaceutical research and development requires substantial funding and a long development period of more than 10 years, but the probability that these efforts will result in a new product or technology is by no means high.」
The company continues to report the risk that development may be discontinued if the expected efficacy or safety cannot be confirmed, after substantial funding and more than 10 years are required for research and development. - FY2019RestatedAnnual report
「Bringing a new drug to market requires substantial funding and a long development period of more than 10 years. Although we will proceed cautiously while confirming efficacy and safety, development may be discontinued along the way.」
The company continues to report the risk that new drug development requires substantial funding and more than 10 years and may be discontinued during development. - FY2018RestatedAnnual report
「Bringing a new drug to market requires substantial funding and a long development period of more than 10 years. Although we will proceed cautiously while confirming efficacy and safety, development may be discontinued along the way.」
The company continues to report the risk that new drug development requires substantial funding and a long period and may be discontinued along the way. - FY2017First statedAnnual report
「Bringing a new drug to market requires substantial funding and a long development period of more than 10 years. Although we will proceed cautiously while confirming efficacy and safety, development may be discontinued along the way.」
The company explicitly identifies as a risk the substantial funding and more than 10 years required for new drug development, as well as the possibility of discontinuation during development.